A Silver Spring company is looking to build the county’s first net zero facility, a building that would produce enough energy to sustain itself annually.
United Therapeutics —a biotechnology company that works on the development and commercialization of unique medical products — is expanding its campus with the new facility on the corner of Spring Street and Colesville Road in downtown Silver Spring. The building at 1000 Spring Street will have solar panels, a green roof and special placement of windows to allow for natural light and cross breezes to push hot air out of the facility, among other environmentally sustainable features, according to a presentation the design team gave to the Silver Spring Citizens Advisory Board on July 8.
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems (NPDCS). This technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. The direct delivery of chemotherapeutic drugs into the tumors has been shown to result in increased efficacy and reduced toxicity.
The NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling moiety which directs the drug into the tumor. This approach minimizes the levels of freely circulating anti-cancer agents in the body, which can dramatically reduce potential adverse events, and maximizes anti-tumor activity by accumulating in the cancer tumor. NPDCS is a broad platform that has the potential to generate multiple therapeutic candidates going forward.
Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of General George A. Joulwan (retired) to the company’s Board of Directors. General Joulwan has a highly distinguished military career that spans 36 years from 1961 to his retirement in 1997. Highlights of General Joulwan’s military service include: Serving as Supreme Allied Commander Europe (SACEUR); Commander in Chief, U.S. Southern Command; Commanding General, V Corps and Commanding General, 3rd Armored Division, United States Army Europe and U.S. Seventh Army, Germany. He has received numerous military decorations and foreign awards and decorations for his bravery and service, including two Silver Stars for valor.
Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions, stated, “General Joulwan has devoted his four-decade career to serving the country, protecting our freedoms, and architecting peace around the world. He is a true and distinguished public servant, who is highly-respected in the global military community. As we expand our portfolio with specialized products that address the needs of U.S. and worldwide governments, his expertise and stature will be invaluable in guiding Emergent’s management team towards further growth.”
Overseas medical technology companies continue to stream into Greater Boston, lured by the area’s famous ecosystem of researchers, startups, and potential collaborators.
One company that flew in under the radar was Qiagen N.V., a Dutch holding company with corporate offices in Germany, which quietly acquired two privately held Massachusetts companies last year and may—or may not—be expanding its foothold in the Boston area.
Montgomery Business Development Corporation is pleased to announce the launch of their new website montgomerybusiness.org.
The enhanced website includes business-friendly features, data resources and information to support existing and future business and development in our vibrant economy.
About 20 kids garbed in lab coats, booties and goggles entered a laboratory on Friday through a door marked with a bright-red “BIOHAZARD” sticker.
Filling the small room, they gathered around lab coordinator and microbiologist Cindy Reichelderfer, who held up several petri dishes in which scientists had tested for the presence of anthrax.
Johns Hopkins researchers have coaxed stem cells into forming networks of new blood vessels in the laboratory, then successfully transplanted them into mice, a technique that could potentially be used to make blood vessels genetically matched to individual patients, the investigators say.
Their research results appear online this week in the Proceedings of the National Academy of Sciences.
The Maryland Industrial Partnerships (MIPS) program, an initiative of the Maryland Technology Enterprise Institute (Mtech) in the A. James Clark School of Engineering at the University of Maryland, has awarded $3.8 million to 17 teams combining Maryland companies with university researchers to bring technology products closer to market, program officials announce today.
MIPS, a technology acceleration program, grants money matched with company funds to faculty engaged in each project.
The Maryland Technology Development Corp. (Tedco) has invested $1.1 million in 14 state startups.
The grants were made through the organization’s Technology Commercialization Fund. The money will be put toward advancing the each company’s technology and product commercialization efforts.
Johns Hopkins Hospital has reclaimed the top position on U.S. News & World Report’s 2013-2014 list of best hospitals.
The return to No. 1 comes a year after Massachusetts General Hospital edged out Hopkins for the top spot on last year’s honor roll list. Hopkins had been No. 1 since 1991.
Venture capitalists invested $318 million in young Maryland companies from April through June, an increase of 115 percent from the first quarter, according to a report released Friday by PricewaterhouseCoopers.
About half of that financing, or $150 million, went to Precision for Medicine Inc., a Chevy Chase company that provides services for medical drug discovery, the report said. That was the highest amount any business in the country raised in the quarter and was matched only by a New York e-commerce website.
The D.C. region raised $418 million in venture funding in April, May and June, according PricewaterhouseCoopers’ MoneyTree report, more than twice the total of second quarter 2012.
The “DC/Metroplex,” as defined by PWC, includes far-flung areas of Virginia and Maryland, not just the District and its suburbs. With the strong second quarter haul, the region has raised nearly as much in the first half of 2013 ($704 million) as it did all of last year ($735 million). For comparison, companies in the area raised $203 million in Q2 2012, and $286 million in the first three months of 2013.
NCATS Research & Development Day will provide the unique opportunity to showcase the projects and technologies that have been incubating in a variety of NCATS drug development programs, including Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs), to an audience of biopharmaceutical companies, venture capital, angel investors, foundations, and others. The object is to connect our collaborators with strategic partners that will provide financial and technical support to bring potential novel therapeutics to patients. The event will be held:
When: Wednesday July 24, 2013 from 4:30 PM to 7:00 PM EDT
Where: Growlers 227 E Diamond Ave Gaithersburg, MD 20877
Join us for a co-hosted BioBuzz and Women In Bio event with our sponsor, Social & Scientific Systems, Inc., along with many others from the local biotech industry at another exciting BioBuzz event on July 24th from 4:30 – 7:00 p.m. in Gaithersburg. Due to an overwhelming positive response to the location, we’re continuing to holding the event this month at Growlers in Old Towne Gaithersburg. We’re excited to see all of you soon, so please register today!
This announcement encourages applications that propose to develop a point of care device for the diagnosis of sickle cell disease (SCD) in infants and young children in low-income and low-resource settings. The aim of this program is to provide rapid diagnosis of SCD to children such that appropriate therapy can be given to reduce the risk of future complications.
Monday, August 19, 2013 – Wednesday, August 21, 2013
Time: 7:00 a.m. – 5:00 p.m.
Location: Natcher Conference Center 45 Center Drive Bethesda, MD 20892
Sponsored by: Blood Diseases Program Division of Blood Diseases and Resources National Heart, Lung, and Blood Institute National Institutes of Health Department of Health and Human Services
National Cancer Institute scientists have released the largest-ever database of cancer-related genetic variations, providing researchers the most comprehensive way so far to figure out how to target treatments for the disease.
Open access worldwide to the new database, based on genome studies, is expected to help researchers accelerate development of new drugs and better match patients with therapies, NCI said in a statement on Monday.
We often hear public leaders say “our diversity is our strength,” which has become somewhat a cliché over the years. While I don’t doubt their sincerity in believing what they say, I wonder how many truly understand what it means to have a large, diverse, and global population in their communities.
This past weekend, I attended the Chinese Biopharmaceutical Association’s (CBA) 18th annual conference, which attracted scientists, educators, businesses and entrepreneurs from the region as well as delegations from several cities in China. It was a high-energy conference hosted by an all-volunteer crew of local community members.
If there’s one thing everyone in healthcare can probably agree on right now, it’s that there is an awful lot of data being generated each and every day. What to do with that data, however, is another question.
As Ted Driscoll, digital health director at venture capital firm Claremont Creek Ventures, sees it, the explosion of data is a definite boon for personalized medicine. Indeed, he said recently, “Medicine is becoming synonymous with big data – the data sets are just huge, now – but we had to wait for the IT revolution to happen and mature” in order to begin to put that data to use.
The year is only half over, but one of the biggest biotech stories of 2013 is going to be the resurgence of the biotech IPO market. It’s a good news/bad news story, depending on where you stand, and how far you look out into the future.
First, the good. The IPO surge is a vote of confidence in biotech from generalist investors who have spent years ignoring the industry. It’s good news for biotech entrepreneurs and venture capitalists who back them. A lot of money will get pumped into researching and developing drugs for diseases that have been long neglected, like Duchenne Muscular Dystrophy. Regional innovation clusters will get a boost. Many small companies will have more negotiating leverage when they talk to Big Pharma companies about acquisitions. It might spur more much-needed venture investment in biotech startups.
Biotechnology companies can access financial and management resources through venture capitalist (VC) firms. An analysis of 1,490 VC investments shows that country-of-origin (CO) of biotech companies has an effect on the participation by VC firms in various biotech subsectors. Specifically, it is found that US biotech companies tend to have higher amount received per VC firm, greater number of VC firms investing in them and greater biotech investment experience of the investing VC firms. Asia-Pacific biotech companies have consistently less VC firms investing in them and these investing VC firms tend to have less biotech investment experience. VC firms with greater biotech investment experience are also investing in European biotech companies more than those from the Americas less US. CO also correlates with outcomes in the four of the six key biotech subsectors studied. These findings suggest a strong CO effect of VC investment in biotech companies.
“We are a team of guerrilla fundraisers who have launched a global campaign to fund research into a potential treatment for the cancer that killed Steve Jobs. The potential therapy, a cancer-busting virus, is currently sitting in a freezer in Sweden – but it can’t be tested for lack of just £2million” was iCancer’s pitch on Indiegogo, a crowdfunding portal. The company brought in more than $160,000 from this campaign.
Microryza is another crowdfunding platform exclusively for scientific research projects, available only to PhDs and professors who can attempt to raise money through this private channel instead of applying for grants. “This solution helps close the gap for potential and promising, but unfunded projects,” Bill Gates says about Microryza. With Kickstartr’s popularity, there has been an explosion of growth in crowdfunding portals, both general as well as ones targeting a specific niche.
When it comes to lending to tech startups, Silicon Valley Bank has an impressive grip on the market. The Santa Clara, Calif.-based institution has been in the D.C. area 15 years and claims half of the region’s venture-backed companies as its clients. The bank, which has $21.5 billion in assets, has grown its Tysons Corner team by 25 percent in the past year to 10 people. I caught up with Megan Scheffel, who manages the bank’s Mid-Atlantic and Southeastern U.S. regions.
Here’s another reason the dysfunctional federal budget process is bad for Americans: besides hurting the economy and hitting us in the pocketbook, partisan feuding over budget cuts could undermine our health and even shorten our lives.
That’s because House Majority Leader Eric Cantor and others in Congress have been using the budget process to target research in the behavioral and social sciences for elimination, even though they’re indispensable to understanding and improving Americans’ health.
BioHealth Innovation (BHI) is a regionally-oriented, private-public partnership functioning as an innovation intermediary focused on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Maryland.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
